The Intellectual Property Appellate Board’s (IPAB) ruling in favour of the Hyderabad-based generic drug maker Natco Pharma against the German drugmaker, Bayer has reignited the debate over innovation versus access in the health sector.
The ruling allows Natco to produce and market the generic (copycat) version of Bayer’s patented cancer drug Nexavar.
Team Zee Research Group(ZRG) took the opportunity to understand the ramifications of the verdict from Natco Pharma director and chief financial officer P Bhaskara Narayana. Welcoming the judgment, Narayana is of the view that it is a recognition of the importance of human values over commercial considerations.
ZRG: Indian patent appeals board (IPAB) has ruled in favour of Natco Pharma which allows it to sell generic version of Bayer AG’s cancer drug Nexavar. What is your take on this ruling?
No comments:
Post a Comment